Harry D. Bear

17.6k total citations · 5 hit papers
173 papers, 11.5k citations indexed

About

Harry D. Bear is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, Harry D. Bear has authored 173 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Oncology, 69 papers in Immunology and 53 papers in Cancer Research. Recurrent topics in Harry D. Bear's work include Immunotherapy and Immune Responses (51 papers), Breast Cancer Treatment Studies (49 papers) and Immune Cell Function and Interaction (31 papers). Harry D. Bear is often cited by papers focused on Immunotherapy and Immune Responses (51 papers), Breast Cancer Treatment Studies (49 papers) and Immune Cell Function and Interaction (31 papers). Harry D. Bear collaborates with scholars based in United States, Canada and United Kingdom. Harry D. Bear's co-authors include Norman Wolmark, Eleftherios P. Mamounas, Richard G. Margolese, D. Lawrence Wickerham, Bernard Fisher, Stewart Anderson, Charles E. Geyer, Masoud H. Manjili, André Robidoux and James L. Hoehn and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Harry D. Bear

170 papers receiving 11.2k citations

Hit Papers

Effect of preoperative chemotherapy on the outcome of wom... 1998 2026 2007 2016 1998 2008 2003 2006 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
    1998 1.7k citations Bernard Fisher, John Bryant et al. Journal of Clinical Oncology profile →
  2. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    2008 1.3k citations Priya Rastogi, Stewart Anderson et al. Journal of Clinical Oncology profile →
  3. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    2003 865 citations Harry D. Bear, Stewart Anderson et al. Journal of Clinical Oncology profile →
  4. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    2006 722 citations Harry D. Bear, Stewart Anderson et al. Journal of Clinical Oncology profile →
  5. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
    2012 394 citations Eleftherios P. Mamounas, Stewart Anderson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry D. Bear United States 43 6.6k 6.4k 3.5k 1.9k 1.8k 173 11.5k
Anthony Lucci United States 56 5.5k 0.8× 6.1k 1.0× 2.3k 0.7× 764 0.4× 2.4k 1.3× 254 11.3k
David W. Ollila United States 44 4.6k 0.7× 4.3k 0.7× 2.3k 0.7× 631 0.3× 1.8k 1.0× 173 8.1k
Frédéric Bibeau France 49 6.3k 1.0× 3.0k 0.5× 2.5k 0.7× 888 0.5× 1.7k 0.9× 193 10.7k
Tari A. King United States 48 3.9k 0.6× 5.6k 0.9× 3.0k 0.9× 605 0.3× 2.1k 1.2× 288 9.4k
Isabelle Bedrosian United States 54 4.0k 0.6× 5.8k 0.9× 3.5k 1.0× 574 0.3× 2.7k 1.5× 238 9.3k
Harry Hollema Netherlands 61 4.0k 0.6× 2.3k 0.4× 2.3k 0.7× 1.8k 1.0× 2.0k 1.1× 229 11.9k
Hans Tesch Germany 49 5.3k 0.8× 2.7k 0.4× 2.8k 0.8× 1.8k 0.9× 368 0.2× 346 9.5k
P Pouillart France 55 5.1k 0.8× 3.2k 0.5× 1.7k 0.5× 1.4k 0.7× 1.2k 0.7× 262 9.1k
Jelle Wesseling Netherlands 55 4.3k 0.7× 5.0k 0.8× 2.2k 0.6× 592 0.3× 1.2k 0.7× 281 10.7k
Lynn C. Hartmann United States 59 4.9k 0.7× 4.4k 0.7× 2.9k 0.8× 1.1k 0.6× 1.5k 0.8× 203 13.0k

Countries citing papers authored by Harry D. Bear

Since Specialization
Citations

This map shows the geographic impact of Harry D. Bear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry D. Bear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry D. Bear more than expected).

Fields of papers citing papers by Harry D. Bear

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry D. Bear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry D. Bear. The network helps show where Harry D. Bear may publish in the future.

Co-authorship network of co-authors of Harry D. Bear

This figure shows the co-authorship network connecting the top 25 collaborators of Harry D. Bear. A scholar is included among the top collaborators of Harry D. Bear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry D. Bear. Harry D. Bear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taylor, Caitlin, Jane Meisel, Aimee J. Foreman, et al.. (2023). Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 199(1). 91–98. 5 indexed citations
2.
Fisher, Bernard, John Bryant, Norman Wolmark, et al.. (2023). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology. 41(10). 1795–1808. 18 indexed citations
3.
Mackelenbergh, Marion van, Fenja Seither, Volker Möbus, et al.. (2022). Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer. 166. 185–201. 9 indexed citations
4.
Dillon, Patrick M., et al.. (2022). A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim. SHILAP Revista de lepidopterología. 2022. 1–5. 6 indexed citations
5.
Yu, Xiaofei, Wenjie Liu, Shixian Chen, et al.. (2021). Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity. Journal for ImmunoTherapy of Cancer. 9(1). e001595–e001595. 15 indexed citations
6.
Liu, Zheng, Chunqing Guo, Swadesh K. Das, et al.. (2021). Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy. Cancer Research. 81(9). 2429–2441. 12 indexed citations
7.
Collier, Amber L., Dasom Lee, Richard Hoefer, et al.. (2020). Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers. 12(9). 2392–2392. 229 indexed citations
8.
White, Julia, Kathryn Winter, Reena S. Cecchini, et al.. (2019). Cosmetic Outcome from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 Phase III Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 105(1). S3–S4. 29 indexed citations
9.
Bear, Harry D., Gong Tang, Priya Rastogi, et al.. (2013). Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. Obstetrical & Gynecological Survey. 68(3). 201–202. 64 indexed citations
10.
Ascierto, Maria Libera, Michael O. Idowu, Yingdong Zhao, et al.. (2013). Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine. 11(1). 145–145. 81 indexed citations
11.
Adams, Barbara J., et al.. (2013). The Role of Margin Status and Reexcision in Local Recurrence Following Breast Conservation Surgery. Annals of Surgical Oncology. 20(7). 2250–2255. 31 indexed citations
12.
Mamounas, Eleftherios P., Stewart Anderson, James J. Dignam, et al.. (2012). Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology. 30(32). 3960–3966. 394 indexed citations breakdown →
13.
Mian, Omar Y., Shou Zhen Wang, Sheng Zu Zhu, et al.. (2011). Methyl-Binding Domain Protein 2–Dependent Proliferation and Survival of Breast Cancer Cells. Molecular Cancer Research. 9(8). 1152–1162. 40 indexed citations
14.
Kmieciak, Maciej, Kyle K. Payne, Michael O. Idowu, et al.. (2011). Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. Journal of Translational Medicine. 9(1). 35–35. 18 indexed citations
15.
Worschech, Andrea, Maciej Kmieciak, Keith L. Knutson, et al.. (2008). Signatures Associated with Rejection or Recurrence in HER-2/ neu –Positive Mammary Tumors. Cancer Research. 68(7). 2436–2446. 32 indexed citations
16.
Morales, Johanna K., Maciej Kmieciak, Laura Graham, et al.. (2008). Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunology Immunotherapy. 58(6). 941–953. 49 indexed citations
17.
Graham, Laura, et al.. (2004). Adoptive immunotherapy (AIT) of established tumors with tumor antigen peptide-sensitized T cells. Cancer Research. 64. 1264–1264. 2 indexed citations
18.
Bear, Harry D., et al.. (1998). Variation in the use of breast-conserving therapy for Medicare beneficiaries in Virginia: clinical, geographic, and hospital characteristics.. PubMed. 6(2). 63–9. 12 indexed citations
19.
20.
Tuttle, Todd M. & Harry D. Bear. (1991). Generation of cytotoxic T lymphocytes (CTL) with phorbol ester and calcium ionophore. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony Lucci Breakdown of academic impact, for papers by David W. Ollila Breakdown of academic impact, for papers by Frédéric Bibeau Breakdown of academic impact, for papers by Tari A. King Breakdown of academic impact, for papers by Isabelle Bedrosian Breakdown of academic impact, for papers by Harry Hollema Breakdown of academic impact, for papers by Hans Tesch Breakdown of academic impact, for papers by P Pouillart Breakdown of academic impact, for papers by Jelle Wesseling Breakdown of academic impact, for papers by Lynn C. Hartmann
Rankless by CCL
2026